Last updated on August 2019

A Study of ABBV-181 in Participants With Advanced Solid Tumors


Brief description of study

This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-181. This study will also evaluate the safety and tolerability of ABBV-181 in combination with Rovalpituzumab Tesirine and ABBV-181 in combination with venetoclax. The study will consist of 3 parts: ABBV-181 monotherapy dose escalation and expansion, ABBV-181 in combination with Rovalpituzumab Tesirine and ABBV-181 in combination with venetoclax.

Clinical Study Identifier: NCT03000257

Find a site near you

Start Over